{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:25:49Z","timestamp":1760865949416},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jceh.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T13:22:48Z","timestamp":1442841768000},"page":"221-238","source":"Crossref","is-referenced-by-count":16,"title":["Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015"],"prefix":"10.1016","volume":"5","author":[{"given":"Pankaj","family":"Puri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil C.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek A.","family":"Saraswat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subrat K.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radha K.","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv K.","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivaram P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh K.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Amarapurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod K.","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Duseja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmesh","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Shalimar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushal","family":"Madan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Pande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aabha","family":"Nagral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Premashis","family":"Kar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Koshy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarender S.","family":"Puri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.E.","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Thareja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2015.09.002_bib0410","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD\/IDSA Guidance Panel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0415","series-title":"Guidelines for the screening care and treatment of persons with hepatitis infection","author":"Anon","year":"2014"},{"key":"10.1016\/j.jceh.2015.09.002_bib0420","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"Recommendations on treatment of hepatitis C 2015","volume":"63","author":"EASL","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0425","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1155\/2015\/692408","article-title":"An update on the management of chronic hepatitis C: 2015 consensus guidelines from the Canadian Association for the Study of the Liver","volume":"29","author":"Myers","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0430","first-page":"388","article-title":"Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era","volume":"72","author":"Berden","year":"2014","journal-title":"Neth J Med"},{"key":"10.1016\/j.jceh.2015.09.002_bib0435","series-title":"Sofosbuvir for treating chronic hepatitis C","author":"NICE technology appraisal guidance 330","year":"2015"},{"key":"10.1016\/j.jceh.2015.09.002_bib0440","first-page":"104","article-title":"Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India","volume":"4","author":"Puri","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0445","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jceh.2014.06.001","article-title":"Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part II: INASL recommendations for management of HCV in India","volume":"4","author":"Puri","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0450","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2014.09.019","article-title":"Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings","volume":"61","author":"Ford","year":"2014","journal-title":"J Hepatol"},{"issue":"suppl. S1","key":"10.1016\/j.jceh.2015.09.002_bib0455","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jvh.12351","article-title":"The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm \u2013 volume 2","volume":"22","author":"Hatzakis","year":"2015","journal-title":"J Viral Hepat"},{"issue":"suppl. S1","key":"10.1016\/j.jceh.2015.09.002_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvh.12371","article-title":"Estimates on HCV disease burden worldwide \u2013 filling the gaps","volume":"22","author":"Wedemeyer","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jceh.2015.09.002_bib0465","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2013.02.039","article-title":"Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies","volume":"144","author":"Chen","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0470","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/S0168-8278(13)60850-8","article-title":"High concordance of SVR4, SVR12 and SVR24 in patients with HCV infection who have received treatment with sofosbuvir","volume":"58","author":"Lawitz","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0475","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1053\/jhep.2000.9112","article-title":"Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA","volume":"32","author":"Tanaka","year":"2000","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jceh.2015.09.002_bib0480","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bjid.2012.10.028","article-title":"Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings?","volume":"17","author":"Chakravarti","year":"2013","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jceh.2015.09.002_bib0485","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/cid\/ciu782","article-title":"Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection","volume":"60","author":"Cresswell","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jceh.2015.09.002_bib0490","doi-asserted-by":"crossref","first-page":"e9147","DOI":"10.5812\/hepatmon.9147","article-title":"Hepatitis C virus (HCV) infection rate among seronegative hemodialysis patients screened by two Methods; HCV core antigen and polymerase chain reaction","volume":"13","author":"Moini","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1016\/j.jceh.2015.09.002_bib0495","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jcv.2015.02.015","article-title":"Performance of architect HCV core antigen test with specimens from US plasma donors and injecting drug users","volume":"66","author":"Mixson-Hayden","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0500","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcv.2012.05.008","article-title":"Clinical utility of the architect HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection","volume":"55","author":"Vermehren","year":"2012","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0505","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0255-0857.31060","article-title":"Significance of the hepatitis C virus (HCV) core antigen as an alternative plasma marker of active HCV infection","volume":"25","author":"Daniel","year":"2007","journal-title":"Int J Med Microbiol"},{"issue":"22","key":"10.1016\/j.jceh.2015.09.002_bib0510","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.3748\/wjg.v20.i22.6701","article-title":"Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment","volume":"20","author":"Tillmann","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0515","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1665-2681(19)30862-2","article-title":"Comparison of two diagnostic algorithms for the identification of patients with HCV viremia using a new HCV antigen test","volume":"13","author":"Reyes-Mendez","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0520","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0973-6883(12)60098-X","article-title":"The distribution of genotype and allelic frequency of IL28B gene polymorphisms in Andhra Pradesh, India","volume":"2","author":"Sivaprasad","year":"2012","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0525","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2015.09.002_bib0530","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"Clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"EASL-ALEH","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0535","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cld.2014.09.007","article-title":"Contemporary assessment of hepatic fibrosis","volume":"19","author":"Bonder","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2015.09.002_bib0540","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0545","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2015.09.002_bib0550","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2015.09.002_bib0555","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2015.09.002_bib0560","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with HCV genotype 3 infection and treatment-experienced patients with cirrhosis and HCV genotype 2 infection","author":"Foster","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0565","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jceh.2015.09.002_bib0570","first-page":"1380A","article-title":"Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study","volume":"58","author":"Lawitz","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0575","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(14)60010-6","article-title":"Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy","volume":"60","author":"Esteban","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0580","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","volume":"381","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2015.09.002_bib0585","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial","volume":"310","author":"Osinusi","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jceh.2015.09.002_bib0590","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/S0168-8278(13)60847-8","article-title":"Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study","volume":"58","author":"Lalezari","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0595","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/j.gastro.2014.12.027","article-title":"The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis","volume":"148","author":"Pearlman","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0600","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/j.gastro.2014.10.027","article-title":"FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin","volume":"147","author":"Mishra","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0605","first-page":"219A","article-title":"Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real world experience in a diverse, longitudinal observational cohort","volume":"60","author":"Jensen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0610","first-page":"220A","article-title":"Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population","volume":"60","author":"Dieterich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0615","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.10.044","article-title":"Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry","volume":"62","author":"Ruane","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0620","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2015.04.023","article-title":"Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4","volume":"63","author":"Doss","year":"2015","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jceh.2015.09.002_bib0625","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12664-010-8004-z","article-title":"Response to antiviral treatment in patients with chronic hepatitis C with persistently normal liver enzymes","volume":"29","author":"Sood","year":"2010","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0630","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/0255-0857.62495","article-title":"Infection with hepatitis C virus genotype 3\u2014experience of a tertiary health care center in south India","volume":"28","author":"David","year":"2010","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0635","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s10620-011-1770-3","article-title":"Prediction of sustained virological response to combination therapy with pegylated interferon alfa and RBV in patients with genotype 3 chronic hepatitis C","volume":"56","author":"Tohra","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2015.09.002_bib0640","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hep.20793","article-title":"Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy","volume":"42","author":"Everson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0645","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0650","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2015.09.002_bib0655","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2015.09.002_bib0660","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2015.09.002_bib0665","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1016\/S0168-8278(14)61461-6","article-title":"All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: phase 3 study results","volume":"60","author":"Manns","year":"2014","journal-title":"J Hepatol"},{"issue":"suppl. 1","key":"10.1016\/j.jceh.2015.09.002_bib0670","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0168-8278(14)60070-2","article-title":"Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety","volume":"60","author":"Afdhal","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0675","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.12576","article-title":"Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis","volume":"35","author":"Akhtar","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2015.09.002_bib0680","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/lt.24051","article-title":"Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment","volume":"21","author":"Ruiz","year":"2015","journal-title":"Liver Transpl"},{"issue":"suppl. 1","key":"10.1016\/j.jceh.2015.09.002_bib0685","first-page":"320A","article-title":"Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study","volume":"60","author":"Flamm","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0690","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/gast.2003.50095","article-title":"Interferon-alpha 2b plus RBV in patients with chronic hepatitis C after liver transplantation: a randomized controlled study","volume":"124","author":"Samuel","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0695","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0700","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with RBV","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0705","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jceh.2015.09.002_bib0710","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2015.09.002_bib0715","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation","author":"Forns","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jceh.2015.09.002_bib0720","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C infection: a meta-analysis","volume":"33","author":"Graham","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jceh.2015.09.002_bib0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.jceh.2015.09.002_bib0730","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/QAI.0b013e31815ac47d","article-title":"Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40kD) plus ribavirin in patients with HIV\/hepatitis C virus coinfection","volume":"47","author":"Opravil","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jceh.2015.09.002_bib0735","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00002030-200204120-00001","article-title":"Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel","volume":"16","author":"Soriano","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jceh.2015.09.002_bib0740","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","article-title":"Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study","volume":"385","author":"Molina","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2015.09.002_bib0745","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3851\/IMP2909","article-title":"Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV coinfected patients","volume":"20","author":"Labarga","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jceh.2015.09.002_bib0750","first-page":"122","article-title":"Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease","volume":"42","author":"Saravanan","year":"2009","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jceh.2015.09.002_bib0755","first-page":"183","article-title":"Characteristics of dual infection of hepatitis B and C viruses among patients with chronic liver disease: a study from tertiary care hospital","volume":"26","author":"Chakravarti","year":"2005","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0760","first-page":"253","article-title":"Prevalence of hepatitis B and hepatitis C virus coinfection in chronic liver disease","volume":"44","author":"Xess","year":"2001","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0765","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11901-010-0060-4","article-title":"Current concepts of HBV\/HCV coinfection: coexistence, but not necessarily in harmony","volume":"9","author":"Jamma","year":"2010","journal-title":"Curr Hepat Rep"},{"key":"10.1016\/j.jceh.2015.09.002_bib0770","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1743-422X-9-186","article-title":"The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus\/hepatitis B virus coinfection: a meta-analysis","volume":"9","author":"Liu","year":"2012","journal-title":"Virol J"},{"key":"10.1016\/j.jceh.2015.09.002_bib0775","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2","article-title":"A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma","volume":"75","author":"Donato","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jceh.2015.09.002_bib0780","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jhep.2008.03.028","article-title":"The HEP-NET B\/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV\/HCV coinfection","volume":"49","author":"Potthoff","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0785","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/ndt\/16.1.193","article-title":"Safety of interferon and RBV therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study","volume":"16","author":"Tan","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jceh.2015.09.002_bib0790","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.transproceed.2004.07.025","article-title":"Alpha-interferon with RBV in the treatment of hemodialysis patients with hepatitis C","volume":"36","author":"Mousa","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jceh.2015.09.002_bib0795","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2893.2005.00680.x","article-title":"Pegylated interferon and RBV treatment for hepatitis C in haemodialysis patients","volume":"13","author":"Bruchfeld","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jceh.2015.09.002_bib0800","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2006.12.016","article-title":"The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus RBV in haemodialysed patients awaiting renal transplant","volume":"46","author":"Rendina","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0805","first-page":"16","article-title":"Monotherapy with peginterferon alpha-2b {12kDa} for chronic hepatitis C infection in patients undergoing haemodialysis","volume":"28","author":"Amarapurkar","year":"2007","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.jceh.2015.09.002_bib0810","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7869\/tg.2012.47","article-title":"Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre","volume":"33","author":"Duseja","year":"2012","journal-title":"Trop Gastroenterol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688315004259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688315004259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T10:28:41Z","timestamp":1692008921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688315004259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0973688315004259"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2015.09.002","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}